Imaging for the prognosis of autosomal dominant polycystic kidney disease

Nature Reviews Nephrology

Volumn 6, Issue 2, 2010, Pages 96-106

  Bae, Kyongtae T ^a   Grantham, Jared J ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; RAPAMYCIN;

DISEASE COURSE; ECHOGRAPHY; FLUID INTAKE; FLUID THERAPY; GLOMERULUS FILTRATION RATE; HEMATURIA; HYPERTENSION; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY POLYCYSTIC DISEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; X RAY;

DIAGNOSTIC IMAGING; HUMANS; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; PROGNOSIS;

EID: 76349092280     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2009.214     Document Type: Review

References (50)

1. Grantham, J. J. Clinical practice. Autosomal dominant polycystic kidney disease. N. Engl. J. Med. 359, 1477-1485 (2008).
2. Gabow, P. A. et al. Factors affecting the progression of renal disease in autosomaldominant polycystic kidney disease. Kidney Int. 41, 1311-1319 (1992).
3. Grantham, J. J., Chapman, A. B. & Torres, v. e. volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clin. J. Am. Soc. Nephrol. 1, 148-157 (2006).
4. Grantham, J. J. et al. volume progression in polycystic kidney disease. N. Engl. J. Med. 354, 2122-2130 (2006).
5. Klahr, S. et al. Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. Modification of Diet in Renal Disease Study Group. J. Am. Soc. Nephrol. 5, 2037-2047 (1995).
6. Gregoire, J. R., Torres, v. e., Holley, K. e. & Farrow, G. M. Renal epithelial hyperplastic and neoplastic proliferation in autosomal dominant polycystic kidney disease. Am. J. Kidney Dis. 9, 27-38 (1987).
7. Harris, P. C. & Torres, v. e. Polycystic kidney disease. Annu. Rev. Med. 60, 321-337 (2009).
8. Gattone, v. H. 2nd, Maser, R. L., Tian, C., Rosenberg, J. M. & Branden, M. G. Developmental expression of urine concentration-associated genes and their altered expression in murine infantile-type polycystic kidney disease. Dev. Genet. 24, 309-318 (1999).
9. Gattone, v. H. 2nd, wang, X., Harris, P. C. & Torres, v. e. Inhibition of renal cystic disease development and progression by a vasopressin v2 receptor antagonist. Nat. Med. 9, 1323-1326 (2003).
10. Torres, v. e. et al. effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat. Med. 10, 363-364 (2004).
11. wang, X., Gattone, v. 2nd, Harris, P. C. & Torres, v. e. effectiveness of vasopressin v2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J. Am. Soc. Nephrol. 16, 846-851 (2005).
12. Nagao, S. et al. Increased water intake decreases progression of polycystic kidney disease in the PCK rat. J. Am. Soc. Nephrol. 17, 2220-2227 (2006).
13. TeMPO 3/4 Trial" Tolvaptan efficacy and Safety in Management of Polycystic Kidney Disease and Its Outcomes (TeMPO3/4) ClinicalTrials.gov A service of the U. S. National Institutes of Health [online], http:// clinicaltrials.gov/ct2/show/nct00428948 (2009).
14. Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up Study ClinicalTrials.gov A service of the U. S. National Institutes of Health [online], http://clinicaltrials.gov/ct2/show/ nct00309283 (2009).
15. Octreotide in Severe Polycystic Liver Disease ClinicalTrials.gov A service of the U. S. National Institutes of Health [online], http:// clinicaltrials.gov/ct2/show/nct00426153 (2009).
16. Lanreotide as Treatment of Polycystic Livers (LOCKCYST) ClinicalTrials.gov A service of the U. S. National Institutes of Health [online], http://clinicaltrials.gov/ct2/show/ nct00565097 (2009).
17. edelstein, C. L. Mammalian target of rapamycin and caspase inhibitors in polycystic kidney disease. Clin. J. Am. Soc. Nephrol. 3, 1219-1226 (2008).
18. edelstein, C. L. Therapeutic interventions for autosomal dominant polycystic kidney disease. Nephrol. News Issues 22, 25-26 (2008).
19. Qian, Q. et al. Sirolimus reduces polycystic liver volume in ADPKD patients. J. Am. Soc. Nephrol. 19, 631-638 (2008).
20. weimbs, T. Polycystic kidney disease and renal injury repair: common pathways, fluid flow, and the function of polycystin-1. Am. J. Physiol. Renal Physiol. 293, F1423-F1432 (2007).
21. wu, M. et al. everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease. Kidney Blood Press. Res. 30, 253-259 (2007).
22. weimbs, T. Regulation of mTOR by polycystin-1: is polycystic kidney disease a case of futile repair? Cell Cycle 5, 2425-2429 (2006).
23. Pilot Study of Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD) ClinicalTrials.gov A service of the U. S. National Institutes of Health [online], http://clinicaltrials.gov/ct2/show/ nct00286156 (2006).
24. Sirolimus Treatment in Patients with Autosomal Dominant Polycystic Kidney Disease: Renal efficacy and Safety (SIReNA) ClinicalTrials.gov A service of the U. S. National Institutes of Health [online], http://clinicaltrials.gov/ct2/ show/ nct00491517 (2007).
25. Sirolimus (Rapamune® ) for Autosomal Dominant Polycystic Kidney Disease (ADPKD) ClinicalTrials.gov A service of the U. S. National Institutes of Health [online], http://clinicaltrials. gov/ct2/show/nct00346918 (2008).
26. efficacy, Safety and Tolerability of everolimus in Preventing end-Stage Renal Disease in Patients with Autosomal Dominant Polycystic Kidney Disease ClinicalTrials.gov A service of the U. S. National Institutes of Health [online], http://clinicaltrials.gov/ct2/show/ nct00414440 (2008).
27. Desai, P. J. et al. Bilateral laparoscopic nephrectomy for significantly enlarged polycystic kidneys: a technique to optimize outcome in the largest of specimens. BJU Int. 101, 1019-1023 (2008).
28. Parfrey, P. S. et al. The diagnosis and prognosis of autosomal dominant polycystic kidney disease. N. Engl. J. Med. 323, 1085-1090 (1990).
29. Ravine, D. et al. evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. Lancet 343, 824-827 (1994).
30. Bakker, J. et al. Renal volume measurements: accuracy and repeatability of US compared with that of MR imaging. Radiology 211, 623-628 (1999).
31. O?Neill, W. C. et al. Sonographic assessment of the severity and progression of autosomal dominant polycystic kidney disease: the Consortium of Renal Imaging Studies in Polycystic Kidney Disease (CRISP). Am. J. Kidney Dis. 46, 1058-1064 (2005).
32. Fick-Brosnahan, G. M., Belz, M. M., McFann, K. K., Johnson, A. M. & Schrier, R. w. Relationship between renal volume growth and renal function in autosomal dominant polycystic kidney disease: a longitudinal study. Am. J. Kidney Dis. 39, 1127-1134 (2002).
33. King, B. F., Reed, J. e., Bergstralh, E. J., Sheedy, P. F. 2nd & Torres, v. e. Quantification and longitudinal trends of kidney, renal cyst, and renal parenchyma volumes in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 11, 1505-1511 (2000).
34. Sise, C. et al. volumetric determination of progression in autosomal dominant polycystic kidney disease by computed tomography. Kidney Int. 58, 2492-2501 (2000).
35. Torres, v. e. et al. Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease. Clin. J. Am. Soc. Nephrol. 2, 112-120 (2007).
36. weinreb, J. C. & Kuo, P. H. Nephrogenic systemic fibrosis. Magn. Reson. Imaging Clin. N. Am. 17, 159-167 (2009).
37. Nascimento, A. B. et al. Rapid MR imaging detection of renal cysts: age-based standards. Radiology 221, 628-632 (2001).
38. Bae, K. T., Commean, P. K. & Lee, J. volumetric measurement of renal cysts and parenchyma using MRI: phantoms and patients with polycystic kidney disease. J. Comput. Assist. Tomogr. 24, 614-619 (2000).
39. Chapman, A. B. et al. Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int. 64, 1035-1045 (2003).
40. Bae, K. T. et al. Magnetic resonance imaging evaluation of hepatic cysts in early autosomaldominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. Clin. J. Am. Soc. Nephrol. 1, 64-69 (2006).
41. Thomsen, H. S., Madsen, J. K., Thaysen, J. H. & Damgaard-Petersen, K. volume of polycystic kidneys during reduction of renal function. Urol. Radiol. 3, 85-89 (1981).
42. Fick-Brosnahan, G., Johnson, A. M., Strain, J. D. & Gabow, P. A. Renal asymmetry in children with autosomal dominant polycystic kidney disease. Am. J. Kidney Dis. 34, 639-645 (1999).
43. Fick-Brosnahan, G. M., Tran, Z. v., Johnson, A. M., Strain, J. D. & Gabow, P. A. Progression of autosomal-dominant polycystic kidney disease in children. Kidney Int. 59, 1654-1662 (2001).
44. Ruggenenti, P. et al. Safety and efficacy of longacting somatostatin treatment in autosomaldominant polycystic kidney disease. Kidney Int. 68, 206-216 (2005).
45. Cadnapaphornchai, M. A., McFann, K., Strain, J. D., Masoumi, A. & Schrier, R. w. Prospective change in renal volume and function in children with ADPKD. Clin. J. Am. Soc. Nephrol. 4, 820-829 (2009).
46. Kistler, A. D. et al. Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months. Kidney Int. 75, 235-241 (2009).
47. Bae, K. T. et al. MRI-based kidney volume measurements in ADPKD: reliability and effect of gadolinium enhancement. Clin. J. Am. Soc. Nephrol. 4, 719-725 (2009).
48. Harris, P. C. et al. Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 17, 3013-3019 (2006).
49. Grantham, J. J. et al. Determinants of renal volume in autosomal-dominant polycystic kidney disease. Kidney Int. 73, 108-116 (2008).
50. Lee, Y. R. & Lee, K. B. Reliability of magnetic resonance imaging for measuring the volumetric indices in autosomal-dominant polycystic kidney disease: correlation with hypertension and renal function. Nephron Clin. Pract. 103, c173-c180 (2006).